Frigid Zone Medicine (Dec 2021)

Tranilast treats cold-related hypertension by reducing the expression of NLRP3 inflammasome

  • Yu Hui,
  • Zhou Yun,
  • Duan Yu,
  • Gao Yunlong,
  • Fang Ning,
  • Zhang Jiawei,
  • Li Yue

DOI
https://doi.org/10.2478/fzm-2021-0012
Journal volume & issue
Vol. 1, no. 2
pp. 95 – 101

Abstract

Read online

Cold exposure is associated with increased prevalence of hypertension and the related severe cardiovascular events. Aberrant activation of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome plays an important role in the development of hypertension. Tranilast (TR), an inhibitor of NLRP3, provides a useful pharmacological probe for exploring the role of NLRP3 in pathogenesis associated with inflammation and its potential application as a therapeutic agent. This study was designed to examine the effects of TR on NLRP3 and hypertension in rats exposed to cold environment to simulate the frigid-zone conditions.

Keywords